Welcome to our dedicated page for TENET HEALTHCARE SEC filings (Ticker: THC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TENET HEALTHCARE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TENET HEALTHCARE's regulatory disclosures and financial reporting.
Tenet Healthcare Corp executive vice president and chief operating officer Lisa Y. Foo reported selling 10,000 shares of Common Stock on 2026-07-29 in an open-market transaction at a weighted average price of $258.03 per share, based on multiple trades between $257.97 and $258.43.
After this sale, Foo directly holds 32,053 shares of Tenet Healthcare Common Stock. The Rule 10b5-1 trading-plan checkbox was not marked, and the insider has undertaken to provide detailed trade-by-trade pricing information upon request to the company, its security holders, or SEC staff.
Tenet Healthcare Corporation reported higher profitability for the quarter ended June 30, 2026. Net operating revenues rose to $5,628 million from $5,271 million, and operating income increased to $1,501 million from $823 million, helped by solid volume growth in both Hospital Operations and Ambulatory Care.
Results were also boosted by $413 million of revenue from contract termination in the quarter and $826 million year‑to‑date related to the Omnibus Agreement with CHI. Net income available to Tenet common shareholders reached $826 million for the quarter and $1,528 million for the first half, with diluted EPS of $9.84 and $17.81, respectively.
Cash from operating activities increased to $2,226 million in the first half of 2026, supporting capital spending of $348 million and share repurchases of $1,360 million, as Tenet bought back 7.021 million shares. Cash and cash equivalents were $2.170 billion at June 30, 2026, with long‑term debt of $13,248 million and full $1,900 million revolver availability.
Company THC filed a notice of proposed sales of common stock. The filing lists 10,000 common shares to be sold through Fidelity Brokerage Services LLC on July 29, 2026, with an aggregate market value of $2,580,295.03, while 86,137,000 shares are outstanding.
The disclosure also notes upcoming restricted stock vesting transactions: 2,953 common shares vesting on February 28, 2026 and 7,047 common shares vesting on March 1, 2026, both categorized as compensation from the issuer.
Tenet Healthcare Corp director Christopher S. Lynch reported selling 3,837 shares of Common Stock on July 27, 2026, in an open-market or private transaction at $243.44 per share. Following the sale, he directly owns 9,568 shares. The Rule 10b5-1 trading plan checkbox was not marked.
Tenet Healthcare Corp executive Paola M. Arbour, EVP and Chief Information Officer, sold 10,878 shares of common stock on July 27, 2026 in a transaction reported as a sale in open market or private transactions at a weighted average price of $243.90 per share, with individual prices ranging from $243.82 to $244.08. Following this sale, she directly holds 18,413 shares of Tenet Healthcare common stock. The transaction was not marked as made under a Rule 10b5-1 trading plan.
Tenet Healthcare Corp director James L. Bierman reported selling 5,000 shares of Common Stock on July 27, 2026, in an open-market or private transaction at a weighted average price of $244.96 per share. The sales occurred between $244.95 and $245.29 and left him with 31,604 directly owned shares.
THC reports a planned sale of common stock under a Form 144 notice. The filing lists 10,878 shares of common stock held at Fidelity Brokerage Services LLC, with a reported value of 2,653,158.70, to be sold on the NYSE on or after July 27, 2026.
The holder also reports prior acquisitions of common shares through restricted stock vesting as compensation, including 1,697 shares on March 1, 2025 and additional grants of 768, 4,446, and 3,967 shares on dates in February 2026. The section for securities sold during the past three months does not list any transactions.
Tenet Healthcare Corporation (THC) reports a planned sale of 5,000 shares of common stock through Fidelity Brokerage Services LLC. The shares have an aggregate market value of $1,224,808.00, with 86,137,000 shares of common stock outstanding and an approximate sale date of July 27, 2026.
The shares relate to prior restricted stock vesting events on May 22, 2026 (1,318 shares) and May 26, 2026 (3,682 shares), both identified as compensation awards from the issuer.
Tenet Healthcare reported strong results for the quarter ended June 30, 2026. Net operating revenues were $5.628 billion, up 6.8% year over year. Net income available to common shareholders rose to $826 million, or $9.84 per diluted share, from $288 million, or $3.14, in 2025. Adjusted diluted EPS increased 52.2% to $6.12. Consolidated Adjusted EBITDA was $1.304 billion, up 16.3%, with a 23.2% margin, and management indicated this exceeded prior second‑quarter guidance.
Ambulatory Adjusted EBITDA grew to $542 million, while Hospital Adjusted EBITDA increased to $762 million with margin improving to 18.0%, supported by higher acuity and additional Medicaid supplemental revenues. For the first six months, net cash from operations was $2.226 billion. The company repurchased 5.68 million shares for $1.042 billion in the quarter, and the board approved a $2.0 billion expansion of the repurchase program, leaving $2.13 billion authorized. Tenet raised its 2026 outlook, guiding to Adjusted EBITDA of $4.83–$5.03 billion and adjusted free cash flow of $2.725–$3.025 billion.
Tenet Healthcare director J. Robert Kerrey reported open-market sales of company common stock. On May 28, 2026, he sold a total of 5,638 shares in multiple transactions at weighted average prices within ranges from $172.63 to $178.08 per share, as detailed in the footnotes. After these sales, he directly owns 16,804 shares of Tenet Healthcare common stock.